Skip to main
SER

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics Inc is advancing its pipeline candidates, notably in high-value indications, which bodes well for future revenue potential. The company's innovative POZ Platform delivery technology addresses existing limitations in drug delivery, enhancing the efficacy of challenging small molecules, particularly in the treatment of neurological diseases and pain. Additionally, the potential clinical success of SER-270 could significantly contribute to long-term financial forecasts, further underscoring the favorable outlook for the company's valuation, especially given the anticipated global acceptance of SER-252.

Bears say

Serina Therapeutics Inc. reported a consistent net loss of $0.64 per share, reflecting ongoing financial challenges for the company. The outlook is further complicated by several risks including potential delays in advancing their lead candidate SER-252 into clinical assessments, difficulties in achieving regulatory approvals, and slower-than-anticipated market uptake due to competitive pressures. Additionally, the company's net loss forecast for 2025 has been significantly revised upward to $2.01 per share from a previous estimate of $0.36, highlighting concerns regarding its financial viability and operational execution.

SER has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 2 analysts, SER has a Strong Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.